Your browser doesn't support javascript.
loading
Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial.
Rha, Sun Young; Choueiri, Toni K; Matveev, Vsevolod B; Alyasova, Anna; Hong, Sung-Hoo; Gordoa, Teresa Alonso; Gurney, Howard; Bjarnason, Georg A; Buchler, Tomas; Pedrazzoli, Paolo; Takagi, Toshio; Park, Se Hoon; Lee, Jae Lyun; Perini, Rodolfo F; He, Cixin S; McKenzie, Jodi A; Eto, Masatoshi.
Afiliação
  • Rha SY; Department of Medical Oncology, Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea.
  • Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Matveev VB; Department of Urology, Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation, Moscow, Russia.
  • Alyasova A; Department of Oncology, Prevoljskiy Region Medical Centre, Novgorod, Russia.
  • Hong SH; Department of Urology, Seoul St. Mary's Hospital, Seoul, South Korea.
  • Gordoa TA; Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Gurney H; Department of Medical Oncology, Macquarie University, Sydney, New South Wales, Australia.
  • Bjarnason GA; Division of Medical Oncology, Department of Medicine, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
  • Buchler T; Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic.
  • Pedrazzoli P; Department of Internal Medicine and Medical Therapy, University of Pavia and Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Takagi T; Department of Urology, Tokyo Women's Medical University Hospital, Tokyo, Japan.
  • Park SH; Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Lee JL; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
  • Perini RF; Clinical Research, Merck & Co., Inc., Rahway, New Jersey, USA.
  • He CS; Biostatistics, Oncology Business Group, Eisai Inc., Nutley, New Jersey, USA.
  • McKenzie JA; Clinical Research, Oncology Business Group, Eisai Inc., Nutley, New Jersey, USA.
  • Eto M; Department of Urology, Kyushu University, Fukuoka, Japan.
Int J Cancer ; 153(6): 1241-1250, 2023 09 15.
Article em En | MEDLINE | ID: mdl-37294085
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Int J Cancer Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Coréia do Sul
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Int J Cancer Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Coréia do Sul